The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl) amino]-7-methoxy-6-[3-[(1R, 6S)-2, 5-dioxa-8-azabicyclo[4.3.0] nonan-8-yl] propoxy] quinazoline dimethanesulfonate, hydrate and a crystalline form thereof； the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.本發明係關於一種EGFR抑制劑的鹽、水合物、晶型及其用途，特別係關於4-[(3-氯-4-氟苯基)氨基]-7-甲氧基-6-{3-[(1R,6S)-2,5-二氧-8-氮雜雙環[4.3.0]壬烷-8-基]丙氧基}-喹唑啉二甲磺酸鹽、其水合物及其晶型；本發明還涉及所述晶型的製備方法、包含所述晶型的藥物組合物及其在治療增殖性疾病中的用途。
